DOR BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- DOR BioPharma's estimated annual revenue is currently $5.9M per year.
- DOR BioPharma's estimated revenue per employee is $155,000
Employee Data
- DOR BioPharma has 38 Employees.
- DOR BioPharma grew their employee count by 0% last year.
DOR BioPharma's People
| Name | Title | Email/Phone |
|---|
DOR BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is DOR BioPharma?
DOR BioPharma, Inc. ( DOR ) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$5.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 38 | 0% | N/A |
#2 | $7.8M | 38 | 6% | $200M |
#3 | $7.4M | 38 | 0% | N/A |
#4 | $7.6M | 38 | -14% | N/A |
#5 | $6.2M | 38 | -39% | N/A |